exscientia

News

Exscientia trims pipeline to focus on top cancer prospects

UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the

News

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus

R&D

12 Questions with Anthony Bradley

“We believe all drugs will be designed using AI by 2030.” At the AI4 Artificial Intelligence Conference in Las Vegas (ai4.io/usa), on 9th August, E

News

Exscientia builds cancer pipeline with two BMS drugs

UK biotech Exscientia has taken a step towards its goal of having four drug candidates in clinical trials next year, after inheriting two precision oncology candidates tha

Digital

AI tissue analysis enables rapid discovery of drug candidate...

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient gr

News